Glaxosmithkline Pharmaceuticals Ltd (GLAXO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,273.80",
    "chg": 14.6,
    "chgp": "0.65%",
    "dir": 1,
    "prev_price": "2,259.20",
    "mcapval": "38,259.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE159A01016",
    "curr_date": "Mar 30",
    "curr_time": "",
    "bse_nse_vol": "1.35 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 30, 2026",
    "traded_date_str": "2026 03 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Markets Rally, But Glaxosmithkline Pharmaceuticals Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-falls-to-52-week-low-of-rs2218-3925143",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_priceRelatedfactors_3925143.png",
        "date": "2026-03-30 13:56:11",
        "description": "Despite a broader market rebound, Glaxosmithkline Pharmaceuticals Ltd has slipped to a fresh 52-week low of Rs 2,218 on 30 Mar 2026, extending its recent downward trajectory amid sector-wide volatility and company-specific valuation concerns."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3923410",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3923410.png",
        "date": "2026-03-30 08:02:06",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3921542",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_mojoScore_3921542.png",
        "date": "2026-03-28 10:10:03",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Technical Setbacks Amid Mixed Momentum Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-technical-setbacks-amid-mixed-momentum-signals-3909199",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3909199.png",
        "date": "2026-03-24 08:03:47",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. The stock’s recent price momentum, combined with mixed readings from key technical indicators such as MACD, RSI, and moving averages, suggests cautious investor sentiment amid broader sector challenges."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3902286",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3902286.png",
        "date": "2026-03-20 08:02:41",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside pressure, raising concerns for investors amid a challenging market backdrop."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3896273",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_mojoScore_3896273.png",
        "date": "2026-03-17 10:10:32",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-signals-3895695",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3895695.png",
        "date": "2026-03-17 08:02:53",
        "description": "Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and technical indicators reveal a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-faces-bearish-momentum-amid-technical-downgrade-3892731",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_technicaldot_3892731.png",
        "date": "2026-03-16 08:02:03",
        "description": "Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a recent downgrade of its technical rating from Hold to Sell. The stock’s technical indicators reveal a transition towards bearish trends, with key metrics such as moving averages and Bollinger Bands signalling increased downside risk. This analysis delves into the technical parameters shaping the stock’s outlook and contextualises its performance against broader market benchmarks."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3875587",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/Glaxosmithkline_mojoScore_3875587.png",
        "date": "2026-03-06 10:10:44",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with the latest insights into its performance and outlook."
      }
    ],
    "total": 5168,
    "sid": "793005",
    "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Mar-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30",
      "datetime": "24-Mar-2026",
      "details": "As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "16-Mar-2026",
      "details": "As per attachment",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25",
          "dt": "2025-05-30",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Markets Rally, But Glaxosmithkline Pharmaceuticals Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off

2026-03-30 13:56:11

Despite a broader market rebound, Glaxosmithkline Pharmaceuticals Ltd has slipped to a fresh 52-week low of Rs 2,218 on 30 Mar 2026, extending its recent downward trajectory amid sector-wide volatility and company-specific valuation concerns.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-03-30 08:02:06

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum, underscoring challenges ahead for investors in this mid-cap pharmaceutical stock.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-03-28 10:10:03

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Faces Technical Setbacks Amid Mixed Momentum Signals

2026-03-24 08:03:47

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. The stock’s recent price momentum, combined with mixed readings from key technical indicators such as MACD, RSI, and moving averages, suggests cautious investor sentiment amid broader sector challenges.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-03-20 08:02:41

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action and technical parameters suggest increasing downside pressure, raising concerns for investors amid a challenging market backdrop.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-03-17 10:10:32

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Signals

2026-03-17 08:02:53

Glaxosmithkline Pharmaceuticals Ltd (NSE: 793005) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and technical indicators reveal a nuanced picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-03-16 08:02:03

Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in price momentum, reflected in a recent downgrade of its technical rating from Hold to Sell. The stock’s technical indicators reveal a transition towards bearish trends, with key metrics such as moving averages and Bollinger Bands signalling increased downside risk. This analysis delves into the technical parameters shaping the stock’s outlook and contextualises its performance against broader market benchmarks.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-03-06 10:10:44

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

View All News